Primary prevention of cervical cancer: Myth or reality
The first in the world quadrivalent vaccine (Gardasil®, «Merck and Co.», USA) against four (6, 11, 16, and 18) more significant types of human papilloma virus (HPV) was licensed for the use in the Russian Federation in November 2006. This review of literature presents data on the epidemiology of HPV related diseases, information on the composition, indications, doses, and other aspects of the vaccine use. Results of wide-scale studies indicate almost 100% efficiency of the vaccine in the prevention of high-grade intraepithelial cervical neoplasia, adenocarcinoma <i>in situ</i>, high-grade vulvar and vaginal dysplastic lesions, external genital warts, causally related to HPV vaccine types, and its high immunogenicity and virtually complete safety. These data permit us expect that in the nearest future the quadrivalent HPV vaccine will be included in the Russian National Calendar of vaccinations and will become an important component of the National Public Health Programs of the Russian Federation.